Veracyte, INC Form 4 insider transactions

Veracyte's Chief Commercial Officer, John Leite, had 2,902 shares withheld to cover tax obligations related to restricted stock unit vesting on September 2, 2025.

Veracyte's VP, Chief Accounting Officer, Jonathan Wygant, reported a disposition of 1,648 shares for tax withholding purposes related to restricted stock unit vesting.

Veracyte, Inc. Director Karin Eastham was granted 9,321 restricted stock units, increasing her beneficial ownership to 23,228 shares.

Veracyte, Inc. Director Jens Holstein was granted 9,321 restricted stock units (RSUs) on June 18, 2025, as part of his compensation, aligning his interests with shareholders.

Veracyte, Inc. Director Evan Jones was granted 9,321 restricted stock units, increasing his direct beneficial ownership to 43,664 shares.

Veracyte, Inc. Director Robert S. Epstein was granted 9,321 restricted stock units on June 18, 2025, increasing his beneficial ownership to 73,919 shares.

Veracyte, Inc. Director Eliav Barr was granted 9,321 Restricted Stock Units (RSUs) on June 18, 2025, as part of his compensation, increasing his total beneficial ownership to 51,189 shares.

Veracyte, Inc. Director Muna Bhanji was granted 9,321 restricted stock units of common stock on June 18, 2025, increasing her direct beneficial ownership to 39,310 shares.

Veracyte, Inc. Director Thomas F. Miller has been granted 9,321 restricted stock units (RSUs) as part of his compensation, aligning his interests with shareholders.

Veracyte, Inc. Director David Brent Shafer was awarded 9,321 restricted stock units, increasing his beneficial ownership to 25,828 shares.

Veracyte, Inc. Director Karin Eastham reported the sale of 4,590 shares of common stock on June 13, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Veracyte, Inc. Director Muna Bhanji has sold 4,589 shares of common stock for approximately $26.67 per share, executed under a pre-established Rule 10b5-1 trading plan.

Veracyte's Chief Commercial Officer, John Leite, sold 2,809 shares of common stock on June 4, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Veracyte CEO Marc Stapley reported the withholding of 9,399 shares of common stock to cover tax obligations related to the vesting of Restricted Stock Units, not a discretionary sale.

Veracyte, Inc.'s Senior Vice President and General Counsel, Annie McGuire, reported a disposition of 3,505 shares of common stock on June 2, 2025, solely to cover tax withholding obligations related to vested Restricted Stock Units.

Veracyte, Inc.'s Chief Financial Officer, Rebecca Chambers, reported the withholding of 5,370 shares of common stock to cover tax obligations related to the vesting of Restricted Stock Units.

Veracyte, Inc.'s Chief Commercial Officer, John Leite, reported the disposition of 2,900 shares of common stock to cover tax liabilities associated with the vesting of Restricted Stock Units.

Veracyte, Inc.'s VP, Chief Accounting Officer, Jonathan Wygant, reported a disposition of 1,848 shares of common stock valued at $26.74 per share, solely for tax withholding purposes related to the vesting of Restricted Stock Units.

Veracyte's Chief Scientific & Medical Officer, Phillip G. Febbo, reported a disposition of 2,955 shares of common stock, valued at $26.74 per share, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Jonathan Wygant, VP and Chief Accounting Officer of Veracyte, Inc., reports acquisition of restricted stock units and disposal of common stock on March 6, 2025.

Phillip G. Febbo, Chief Scientific & Medical Officer of Veracyte, Inc., reports the acquisition of restricted stock units.

Rebecca Chambers, CFO of Veracyte, Inc., reports acquiring 30,200 shares of common stock and disposing of 143,899 shares on March 6, 2025, according to a Form 4 filing with the SEC.

Chief Commercial Officer John Leite reports acquisition of restricted stock units and subsequent sale of common stock under a 10b5-1 plan.

Annie McGuire, SVP, General Counsel of Veracyte, Inc., reports the acquisition of 30,200 shares of common stock as restricted stock units.

CEO Marc Stapley reports acquiring shares of Veracyte stock and disposing of shares on March 6, 2025.

Phillip G. Febbo, Chief Scientific & Medical Officer of Veracyte, Inc., sold shares of common stock on March 4, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Veracyte's CEO, Marc Stapley, executed sales of common stock on March 4, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Annie McGuire, SVP, General Counsel of Veracyte, Inc., reports the sale of 1,142 shares of common stock on March 4, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Veracyte's VP, Chief Accounting Officer Jonathan Wygant, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Chief Commercial Officer John Leite reports acquisition of shares through PSU vesting and subsequent disposal to cover tax obligations.